Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus

Koffarnus, Robin L.; Wargo, Kurt A.; Phillippe, Haley M.

doi:10.1345/aph.1r754

Cited by 19 publications

(17 citation statements)

References 22 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, Trabectedin is a known anti-tumor drug and has been approved for the treatment of advanced soft tissue sarcoma (31). Rosiglitazone and Troglitazone are anti-diabetic drugs that belong to the thiazolidinedione class and act as PPAR gamma agonists (32, 33). Our result suggests the program regulated by these drugs might be associated with survival of patients with liposarcoma.…”

Section: Resultsmentioning

confidence: 99%

Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value

Cheng

Lou

Andrews

et al. 2016

Molecular Cancer Research

View full text Add to dashboard Cite

Liposarcoma is the second most common form of sarcoma, which has been categorized into four molecular subtypes, which are associated with differential prognosis of patients. However, the transcriptional regulatory programs associated with distinct histological and molecular subtypes of liposarcoma have not been investigated. This study uses integrative analyses to systematically define the transcriptional regulatory programs associated with liposarcoma. Likewise, computational methods are used to identify regulatory programs associated with different liposarcoma subtypes as well as programs that are predictive of prognosis. Further analysis of curated gene sets was used to identify prognostic gene signatures. The integration of data from a variety sources including gene expression profiles, transcription factor (TF) binding data from ChIP-seq experiments, curated gene sets, and clinical information of patients indicated discrete regulatory programs (e.g., controlled by E2F1 and E2F4) with significantly different regulatory activity in one or multiple subtypes of liposarcoma with respect to normal adipose tissue. These programs were also shown to be prognostic, wherein liposarcoma patients with higher E2F4 or E2F1 activity associated with unfavorable prognosis. A total of 259 gene sets were significantly associated with patient survival in liposarcoma, among which >50% are involved in cell cycle and proliferation.

show abstract

Section: Resultsmentioning

confidence: 99%

Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value

Cheng

Lou

Andrews

et al. 2016

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…Rivoglitazone could also ameliorate insulin resistance (49). In clinics, rivoglitazone has been used to treat type 2 diabetes, but rivoglitazone has many adverse effects such as peripheral edema and weight gain (50).…”

Section: Pparmentioning

confidence: 99%

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease

2017

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has been defined as a spectrum of histological abnormalities and is characterized by significant and excessive accumulation of triglycerides in the hepatocytes in patients without alcohol consumption or other diseases. Current studies are targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. Many therapeutic targets have been found and used in clinical studies. Peroxisome proliferator-activated receptors (PPARs) are among the potential targets and have been demonstrated to exert a pivotal role in modulation of NAFLD. Many drugs developed so far are targeted at PPARs. Thus, the aim of this paper is to summarize the roles of PPARs in the treatment of NAFLD.

show abstract

“…Związek ten powodował zmniejszenie odsetka glikozylowanej hemoglobiny o najwyższą wartość ze wszystkich badanych dotychczas tiazolidinedionów, co powoduje, iż wiąże się z nim duże nadzieje kliniczne. Jednak i riwoglitazon nie jest pozbawiony działań niepożądanych typowych dla pozostałych glitazonów wspomnianych powyżej -trwają badania oceniające skuteczność i bezpieczeństwo tego związku w perspektywie długotrwałego stosowania [32].…”

Section: Prace Nad Nowymi Lekami Wykorzystującymi Mechanizm Agonistycunclassified

Agoniści receptorów aktywowanych proliferatorami eroksysomów w farmakoterapii. Obecne znaczenie i perspektywy zastosowania

Dobrek¹

2017

PiS

View full text Add to dashboard Cite

Rivoglitazone: A New Thiazolidinedione for the Treatment of Type 2 Diabetes Mellitus

Cited by 19 publications

References 22 publications

Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value

Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease

Agoniści receptorów aktywowanych proliferatorami eroksysomów w farmakoterapii. Obecne znaczenie i perspektywy zastosowania

Contact Info

Product

Resources

About